Liraglutide

Type 2 Diabetes Management

Liraglutide is used along with diet and exercise to improve blood sugar control in adults and children 10 years of age and older with type 2 diabetes. It helps the body manage glucose levels more effectively.

Reducing Cardiovascular Risk

In adults with type 2 diabetes who also have established heart or blood vessel disease, liraglutide is used to reduce the risk of major cardiovascular events, including:

• Heart attack
• Stroke
• Death from cardiovascular causes

Weight Management

Liraglutide is also used as an addition to a reduced-calorie diet and increased physical activity for chronic weight management. It is prescribed for:

• Adults who have obesity (a body mass index of 30 or higher).
• Adults who are overweight (a body mass index of 27 or higher) and have at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol.
• Children 12 years and older who weigh more than 132 pounds (60 kg) and have a body weight that is considered obese for their age and sex.

Important Limitations

Liraglutide is not used to treat type 1 diabetes or diabetic ketoacidosis. It is also not intended for use in combination with other weight-loss products or other medications that contain the same active ingredient.

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist

Liraglutide belongs to a class of medications known as GLP-1 receptor agonists. It works by mimicking the functions of a naturally occurring hormone called glucagon-like peptide-1, which the body typically releases from the intestines after a person eats.

Blood Sugar Regulation

For individuals with type 2 diabetes, liraglutide helps control blood sugar through several mechanisms:

• Insulin Release: It stimulates the pancreas to release the appropriate amount of insulin when blood sugar levels are high.
• Glucagon Suppression: It reduces the amount of sugar the liver produces by suppressing glucagon, a hormone that normally triggers the liver to release glucose.
• Slower Digestion: It slows the rate at which food moves through the stomach. This delayed gastric emptying helps prevent blood sugar levels from rising too quickly after meals.

Appetite and Weight Management

Liraglutide also targets receptors in the brain that control appetite and satiety. By mimicking the GLP-1 hormone, it helps increase feelings of fullness and decreases hunger. This mechanism can lead to reduced calorie intake, which supports weight loss and long-term weight management.

Common Side Effects

• Nausea and vomiting
• Diarrhea or constipation
• Stomach pain or upset stomach
• Headache
• Dizziness
• Fatigue
• Decreased appetite
• Injection site reactions, such as redness, itching, or a rash

Serious Side Effects

Contact a healthcare professional immediately if you experience any of the following serious symptoms:

• Pancreatitis: Severe, persistent pain in the upper stomach that may move to the back, with or without vomiting.
• Gallbladder problems: Pain in the upper right stomach, fever, or yellowing of the skin or eyes.
• Kidney issues: Changes in the amount or color of urine, or swelling in the legs and feet.
• Severe allergic reactions: Swelling of the face, lips, or throat; difficulty breathing or swallowing; or a severe rash.
• Rapid heartbeat: A racing or pounding heart while at rest.
• Mood changes: New or worsening depression, suicidal thoughts, or unusual changes in behavior.
• Low blood sugar (hypoglycemia): Symptoms such as sudden sweating, shakiness, confusion, or blurred vision, particularly when used with other diabetes medications.

Boxed Warning: Thyroid C-Cell Tumors

In animal studies, liraglutide caused thyroid C-cell tumors. It is currently unknown whether it causes these tumors in humans. This medication is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be aware of potential symptoms such as a lump in the neck, difficulty swallowing, or shortness of breath.

Pancreatitis

Acute pancreatitis, including fatal cases, has been reported in patients using liraglutide. Patients are typically monitored for signs such as persistent, severe abdominal pain that may radiate to the back. If pancreatitis is suspected, the medication should be discontinued immediately and not restarted if the diagnosis is confirmed.

Gallbladder Disease

Liraglutide use is associated with gallbladder problems, including gallstones (cholelithiasis) and inflammation of the gallbladder (cholecystitis). Some cases may be severe enough to require surgical removal of the gallbladder.

Kidney Function

There have been reports of acute kidney injury and the worsening of chronic renal failure in patients treated with liraglutide. These events are often associated with dehydration caused by gastrointestinal side effects like nausea, vomiting, or diarrhea. Monitoring of renal function is recommended, especially when starting the drug or increasing the dose.

Hypoglycemia

The risk of low blood sugar (hypoglycemia) increases when liraglutide is used in combination with insulin or insulin secretagogues, such as sulfonylureas. A reduction in the dose of the concomitant medication may be required to lower this risk.

Other Precautions

• Hypersensitivity: Serious allergic reactions, including anaphylaxis and angioedema, have occurred. If a reaction is suspected, the medication must be stopped and medical attention sought immediately.
• Heart Rate: An increase in resting heart rate can occur. Heart rate should be monitored at regular intervals.
• Suicidal Behavior: In patients using liraglutide for weight management, monitoring for suicidal thoughts, behaviors, or any unusual changes in mood or depression is recommended.
• Gastrointestinal Disease: Liraglutide slows gastric emptying and has not been studied in patients with pre-existing severe gastrointestinal disease, such as gastroparesis.

Pregnancy

Data on the use of liraglutide in pregnant women are limited. In animal studies, the medication was associated with reduced fetal growth and structural abnormalities when given at doses higher than those used in humans. For these reasons, liraglutide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

If liraglutide is being used specifically for weight management, it is typically discontinued once pregnancy is recognized. Weight loss is not recommended for pregnant individuals and may lead to fetal harm.

Breastfeeding

It is not known if liraglutide passes into human breast milk. Research in animals has shown that the drug can be present in milk, but there is no definitive evidence regarding its effect on human infants. Patients should discuss the potential risks and benefits with their healthcare provider before breastfeeding while using this medication.

Available Forms

Liraglutide is provided as a clear, colorless liquid solution. It is administered by injection into the fatty tissue under the skin, a process known as subcutaneous injection.

The medication is supplied in the following format:

• Pre-filled, multi-dose injection pens

These pens are designed for use with disposable needles. The injection is typically administered in the abdomen, thigh, or upper arm.

FDA Approval and Indications

Liraglutide is approved by the U.S. Food and Drug Administration (FDA) for several indications depending on the specific product formulation:

• Type 2 Diabetes: It is used to improve glycemic control in adults and pediatric patients aged 10 years and older.
• Cardiovascular Risk Reduction: It is approved to reduce the risk of major adverse cardiovascular events, such as heart attack or stroke, in adults with type 2 diabetes and established cardiovascular disease.
• Chronic Weight Management: It is approved for use in adults and pediatric patients aged 12 years and older with obesity or who are overweight and have weight-related medical conditions.

Boxed Warning

Liraglutide carries a boxed warning because it has been shown to cause thyroid C-cell tumors in rodents. While it is not known if the drug causes these tumors in humans, it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Regulatory Oversight

The FDA has historically required a Risk Evaluation and Mitigation Strategy (REMS) for liraglutide products. This program was designed to inform healthcare professionals about the potential risks of medullary thyroid carcinoma and acute pancreatitis associated with the medication.

How Liraglutide Works for Weight Loss

Liraglutide belongs to a class of drugs known as GLP-1 receptor agonists. It mimics a naturally occurring hormone in the body that targets areas of the brain responsible for regulating appetite and food intake. By acting on these receptors, the medication helps you feel full sooner and slows the rate at which the stomach empties, which can lead to eating fewer calories.

Who Can Use It

This medication is typically prescribed for weight management in the following groups:

• Adults with obesity (a body mass index or BMI of 30 or higher).
• Adults who are overweight (a BMI of 27 or higher) and also have weight-related medical problems, such as high blood pressure, type 2 diabetes, or high cholesterol.
• Children aged 12 to 17 years who weigh more than 132 pounds (60 kg) and have obesity as defined by their age and sex.

Usage Requirements

Liraglutide is not intended to be used alone. For effective weight loss and maintenance, it must be used in combination with:

• A reduced-calorie meal plan.
• Increased physical activity or a regular exercise routine.

The medication is administered once daily as a subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It is important to follow a healthcare provider's instructions regarding dosage, as the amount is usually increased gradually over several weeks to reduce the risk of stomach-related side effects.